The Invisible Struggle & Flumazenil in Canada in 2026: Unveiling the Challenges of Idiopathic Hypersomnia Care in the Canadian Healthcare System
The TLDR. The Canadian healthcare system fails idiopathic hypersomnia patients through lack of awareness, limited sleep testing access and absence of Health Canada-approved medications. Nevertheless, informed sleep specialists can provide effective management through carefully selected off-label treatments such as flumazenil. Our forthcoming article will examine flumazenil as a potential option for patients who haven’t responded adequately to conventional therapies.